The FDA on Dec. 28 approved TG Therapeutics, Inc.’s Briumvi for the treatment of relapsing forms of multiple sclerosis. The monoclonal antibody will be the third anti-CD20 therapy in the relapsing MS market basket, joining Roche’s Ocrevus and Novartis’ Kesimpta. Briumvi boasts a novel administration, however — a one-hour infusion every six months following its four-hour starting dose. For the treatment of MS, Ocrevus holds covered or better status for 66% of all insured lives under the pharmacy benefit and 92% of lives under the medical benefit. Kesimpta, meanwhile, holds covered or better status for 85% of insured lives under the pharmacy benefit, and 13% of lives under the medical benefit.
SOURCE: MMIT Analytics, as of 1/9/23